PDCD1 and non-small cell lung carcinoma: ICIs, such as anti-programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1), have been demonstrated to prolong overall survival (OS) in patients with metastatic NSCLC and have been approved as first-line systemic therapy for advanced NSCLC (1–3).